Researchers from the University of Pennsylvania found that older prostate cancer patients getting hormone treatment, called androgen deprivation therapy (ADT), were more likely to be diagnosed later with Alzheimer’s disease or dementia. The study was published July 3, 2019 in JAMA Network Open.
The study authors looked at records from about 154,000 prostate cancer patients in the National Cancer Institute’s SEER database. The men, aged 66 years and older, were diagnosed between 1996 and 2003 and were followed for an average of 8 years. More than 62,000 received ADT within 2 years after their diagnosis, and almost 92,000 did not. Results showed that men treated with ADT were more likely to be diagnosed with Alzheimer’s disease or dementia compared to men who did not get ADT. They also found the risk was higher for men who received more doses of ADT.
The link between ADT and dementia has been studied before, but the results have conflicted. The authors say this study is strong because of the large number of patients observed, the long follow-up period, the connection with higher doses of ADT, and the careful controls of medical and socio-economic factors.
However, they acknowledge that more work needs to be done to identify which men may be already at high risk of developing dementia. It can take more than 10 years for someone with dementia to start showing signs. It’s possible that ADT didn’t cause the dementia seen in the study but may have sped up a process that was already taking place.
ADT reduces levels of male hormones in the body, called androgens, to stop them from helping prostate cancer cells grow. It can help some men with high-risk localized or advanced prostate cancer live longer.
But ADT can often cause negative side effects that include reduced sexual desire, impotence, hot flashes, osteoporosis, loss of muscle mass, and depression. The study authors say the risk of dementia is one more possible negative side effect that should be considered when weighing the benefits and risks of ADT, especially for men who have a longer life expectancy because it takes time to develop dementia.
The American Cancer Society medical and editorial content team
Our team is made up of doctors and oncology certified nurses with deep knowledge of cancer care as well as journalists, editors, and translators with extensive experience in medical writing.
Association Between Androgen Deprivation Therapy Use and Diagnosis of Dementia in Men With Prostate Cancer. Published July 3, 2019 in JAMA Network Open. First author Ravishankar Jayadevappa, PhD, University of Pennsylvania, Philadelphia.
American Cancer Society news stories are copyrighted material and are not intended to be used as press releases. For reprint requests, please see our Content Usage Policy.